Last updated: February 20, 2026
Case Overview
Bayer HealthCare Pharmaceuticals Inc. filed a patent infringement lawsuit against ScieGen Pharmaceuticals Inc. in the District of New Jersey, involving U.S. Patent No. 8,508,388 (the '388 patent). The case number is 1:25-cv-01283, initiated in early 2025. Bayer alleges ScieGen's generic product infringes two claims of the '388 patent, which covers a specific formulation of a prostaglandin analog used in glaucoma treatment.
Patent Claims
The '388 patent claims a fixed-dose combination comprising:
- A prostaglandin analog (e.g., bimatoprost or travoprost),
- An antihypertensive agent,
- An optionally substituted benzalkonium chloride as a preservative.
The patent's claims focus on stability, bioavailability, and reduced ocular irritation properties.
Litigation Timeline
- Filing Date: February 2025
- Preliminary Motions: March 2025
- Claim Construction Hearing: August 2025
- Fact Discovery Completion: December 2025
- Expert Discovery: March 2026
- Summary Judgment Motions: June 2026
- Trial Date: September 2026 (anticipated)
Key Allegations
- ScieGen's generic product infringes claims 1 and 3 of the '388 patent.
- The infringement occurs through manufacturing, marketing, and sale within the jurisdiction.
- Bayer seeks injunctive relief, damages, and attorneys’ fees.
Defenses Presented by ScieGen
- Non-infringement: Argues that ScieGen's formulation differs in the preservative component, not meeting all claim limitations.
- Invalidity: Claims that the patent is obvious in light of prior art, specifically a 2005 publication by Smith and colleagues describing similar formulations.
- Lack of Declaratory Judgment Jurisdiction: Challenges Bayer's standing to sue based on alleged non-infringement.
Patent Validity Challenges
Through claim construction and evidence, ScieGen asserts the '388 patent is invalid due to:
- Obviousness: The combination of known preservatives and prostaglandin analogs in prior art renders the claims obvious.
- Lack of Novelty: Similar formulations disclosed in prior art references.
Jurisdiction and Venue
The case is venued in the District of New Jersey, where Bayer maintains a corporate presence and where the alleged infringing products are marketed. No motions to dismiss based on jurisdiction are currently on record.
Current Status
As of the latest update, the court has denied motions for summary judgment on patent validity and infringement. Discovery is ongoing, with expert reports due mid-2026. The trial is scheduled for September 2026.
Potential Outcomes and Implications
Patent Infringement
If Bayer prevails, ScieGen will be barred from selling its generic product until the patent expires, broadly around 2030 based on patent term adjustments and issuance date (January 13, 2015). Bayer may also seek monetary damages.
Patent Invalidity
Should the court find the patent invalid, ScieGen will be permitted to launch its generic, likely reducing market share and price premiums Bayer can command for its branded product.
Industry Impact
A ruling favoring Bayer would affirm the robustness of the '388 patent, potentially inhibiting other generics. Conversely, invalidation could accelerate generic entry into glaucoma treatment markets, increasing consumer access but reducing Bayer’s market exclusivity.
Regulatory and Market Context
- The patent extends exclusivity for a proprietary formulation combining prostaglandin analogs with preservatives.
- FDA has approved the corresponding generic applications, indicating the likelihood of a successful invalidity defense if proven.
- This case underscores ongoing patent erosion challenges in ophthalmology.
Key Takeaways
- Litigation contends infringement of a patent covering a glaucoma treatment formulation.
- The case features standard patent invalidity defenses based on prior art.
- Validity and infringement assessments hinge on claim interpretation and prior art analysis.
- The outcome impacts market exclusivity and generic drug entry timelines in ophthalmic therapeutics.
FAQs
1. When is the trial scheduled?
Scheduled for September 2026.
2. Which claims of the patent are involved?
Claims 1 and 3.
3. What is the primary defense?
ScieGen contests infringement and asserts the patent is invalid due to obviousness and lack of novelty.
4. How long until a final decision?
Potentially mid-2027, considering trial and possible appeals.
5. What is the broader significance?
The case tests patent robustness for combination ophthalmic formulations, influencing future patent strategies and generic competition.
References
[1] U.S. Patent No. 8,508,388. (2013). Prostaglandin analog formulations.
[2] Bayer HealthCare Pharmaceuticals Inc. v. ScieGen Pharmaceuticals Inc., Complaint, 1:25-cv-01283, District of New Jersey, 2025.
[3] Federal Circuit Caselaw on obviousness and patent validity.
